AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential.
Abcellera Biologics Inc. (ABCL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 27,525,640 | $61,382,177 | 0.68% | |
| 2. | OrbiMed Advisors Samuel Isaly | 4,180,768 | $9,323,113 | 0.22% | |
| 3. | Renaissance Technologies Jim Simons | 2,894,029 | $6,453,685 | +17% | 0.01% |
| 4. | Prosight Capital Lawrence Hawkins | 2,815,652 | $6,278,904 | -62% | 2.06% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 2,644,800 | $5,897,904 | +2% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.16 | 343,631 | $742,242.96 | 56,143,640 | 2025-03-11 | Filing | |
| $2.30 | 25,000 | $57,500.00 | 171,000 | 2025-03-10 | Filing | |
| $2.34 | 60,000 | $140,568.00 | 146,000 | 2025-03-06 | Filing | |
| $2.61 | 283,516 | $739,976.76 | 56,086,009 | 2024-08-29 | Filing | |
| $4.46 | 10,000 | $44,600.00 | 86,000 | 2023-11-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.93 | 137,351 | $2,325,352.43 | 128,862 | 2021-09-01 | Filing | |
| $16.95 | 162,649 | $2,756,900.55 | 266,213 | 2021-08-31 | Filing | |
| $25.50 | 100,000 | $2,550,000.00 | 1,003,397 | 2021-06-22 | Filing | |
| $24.03 | 5,598,420 | $134,530,032.60 | 55,604,330 | 2021-06-09 | Filing | |
| $25.50 | 401,580 | $10,240,290.00 | 233,500 | 2021-06-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,671,063 | $34,946,470 | 0.01% | |
| 2. | 13,361,096 | $29,795,244 | 0% | |
| 3. | 11,195,832 | $24,966,706 | 0.02% | |
| 4. | 10,624,185 | $23,691,933 | 0.02% | |
| 5. | 5,082,183 | $11,333,268 | 0% |
News See All
12 Best Canadian Stocks With Huge Upside Potential
Earlier on May 29, Invesco’s Brian Levitt appeared on CNBC's 'The Exchange' to discuss how he thinks now is the time to diversify your portfolio into other parts of the world.
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL.
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis
Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against atopic dermatitis (AD).
13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AbCellera’s First Quarter 2025 Business Update and Conference Call.
13 Best Canadian Penny Stocks to Invest in Now
We define penny stocks as shares trading under $5.00, which usually fall into the small cap category.
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to AbCellera's Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today's interactive broadcast.
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc.
12 Best Canadian Penny Stocks to Buy According to Analysts
According to a report by the Government of Canada, released on December 16, the country's economic outlook has been revised upward, as private-sector economists forecast moderate growth of around 2% in...
Billionaire Hedge Funds
